H.C. Wainwright keeps USD 15.00 target for ImmunityBio stock

Published on 10/17/2026 at 22:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ImmunityBio is scheduled to report results on November 3, 2026. ImmunityBio stock last stood at EUR 8.19 on October 16, 2026, 2.50 percent below the Xetra close.

Target outlook and valuation

H.C. Wainwright maintained a Buy rating and a USD 15.00 target on October 15, 2026.
ImmunityBio is scheduled to report results on November 3, 2026.
ImmunityBio stock costs EUR 8.19 at Lang & Schwarz on October 16, 2026 at 11:00 p.m. CEST, 2.50 percent below the Xetra close of October 16, 2026.
ImmunityBio had a USD 9.7 billion market capitalization and a price-to-earnings ratio of -9.43 on October 16, 2026.

IBRX, US45256X1037, Illustration mit AI erstellt.

H.C. Wainwright maintained a Buy rating and a USD 15.00 price target for ImmunityBio in a note dated October 15, 2026, according to MarketBeat. The target stood 63.40 percent above the Nasdaq price of USD 9.18 on October 16, 2026. The last euro quote stood at EUR 8.19 at Lang & Schwarz on October 16, 2026 at 11:00 p.m. CEST, minus 2.50 percent versus the Xetra close of October 16, 2026 at EUR 8.40.

Results date is November 3, 2026

ImmunityBio is scheduled to report its next results on November 3, 2026, according to BörsenNews.de. The date gives investors the next fixed checkpoint for sales, losses and commercial progress following the latest reported quarter.

Stock sits 26.15 percent below high

On Nasdaq, ImmunityBio last traded at USD 9.18 on October 16, 2026, with a 52-week range of USD 1.95 to USD 12.43. The price was 26.15 percent below the 52-week high and 370.77 percent above the 52-week low. The same session showed 21,439,357 shares of volume against an average of 11,205,264 shares.

Valuation at USD 9.7 billion

ImmunityBio had a market capitalization of USD 9.7 billion and a price-to-earnings ratio of -9.43 on October 16, 2026. The company remains loss-making, while the analyst target provides a separate numerical benchmark rather than a trading recommendation.

Comparison with peers

ImmunityBio (Nasdaq, USD): minus 2.50 percent, P/E -9.43, market capitalization USD 9.7 billion

Gilead Sciences (Nasdaq, USD): minus 0.75 percent, P/E -58.50, market capitalization USD 193.7 billion

Bristol-Myers Squibb (NYSE, USD): minus 1.35 percent, P/E 13.16, market capitalization USD 122.1 billion

Euro quote after the Xetra close

The euro quotation was below the Xetra close of October 16, 2026, while the Nasdaq price remained separate in USD. The next scheduled results date is November 3, 2026.

The further course of trading is shown by the continuously updated real-time quote of ImmunityBio stock.